AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Hutchmed (China) Limited

Declaration of Voting Results & Voting Rights Announcements Dec 31, 2014

10503_dva_2014-12-31_ebcf0503-d3a7-43b3-b66f-9ef48ade8414.html

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0075B

Hutchison China Meditech Limited

31 December 2014

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

Total Voting Rights

London: Wednesday, 31 December 2014: For information purposes, Chi-Med hereby notifies the market that as at 31 December 2014, the issued share capital of the Company consisted of 53,076,676 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 53,076,676 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the FCA's Disclosure Rules and Transparency Rules.

Ends

Enquiries

Chi-Med

Christian Hogg, CEO
Telephone:      +852 2121 8200
Panmure Gordon (UK) Limited Telephone:      +44 20 7886 2500
Richard Gray

Andrew Potts
Citigate Dewe Rogerson

Anthony Carlisle

David Dible
Telephone:      +44 20 7638 9571

Mobile:             +44 7973 611 888

Mobile:             +44 7967 566 919

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13).  For more information, please visit: www.chi-med.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVREAKAFDSFLFEF

Talk to a Data Expert

Have a question? We'll get back to you promptly.